Reneta Hermiz
Overview
Explore the profile of Reneta Hermiz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, et al.
Mol Ther Oncolytics
. 2022 May;
25:174-188.
PMID: 35592387
Clinical studies have demonstrated that local expression of the cytokine IL-12 drives interferon-gamma expression and recruits T cells to the tumor microenvironment, ultimately yielding durable systemic T cell responses. Interrogation...
2.
Han M, Nguyen B, Lee J, Browning E, Zhang J, Mukhopadhyay A, et al.
Mol Cancer Res
. 2022 Mar;
20(6):983-995.
PMID: 35302641
Implications: This DNA-encodable polyclonal T-cell stimulator (membrane-anchored anti-CD3 plasmid) may represent a key addition to intratumoral IL12 therapies in the clinic.
3.
Telli M, Nagata H, Wapnir I, Acharya C, Zablotsky K, Fox B, et al.
Clin Cancer Res
. 2021 Feb;
27(9):2481-2493.
PMID: 33593880
Purpose: Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Antibodies targeting programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) have entered the therapeutic landscape in...
4.
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Algazi A, Twitty C, Tsai K, Le M, Pierce R, Browning E, et al.
Clin Cancer Res
. 2020 May;
26(12):2827-2837.
PMID: 32376655
Purpose: Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral...